Cumberland Pharmaceuticals (CPIX)
(Delayed Data from NSDQ)
$1.61 USD
-0.03 (-1.83%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $1.62 +0.01 (0.62%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for Cumberland Pharmaceuticals Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 18 | 20 | 27 | 25 | 28 |
Receivables | 10 | 13 | 7 | 12 | 10 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 5 | 10 | 8 | 11 | 9 |
Other Current Assets | 3 | 3 | 3 | 2 | 3 |
Total Current Assets | 36 | 46 | 46 | 50 | 50 |
Net Property & Equipment | 0 | 0 | 0 | 1 | 1 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 13 | 8 | 9 | 12 | 16 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 24 | 32 | 25 | 29 | 32 |
Deposits & Other Assets | 3 | 3 | 3 | 3 | 3 |
Total Assets | 82 | 93 | 84 | 96 | 105 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 14 | 11 | 10 | 13 | 12 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 14 | 18 | 9 | 11 | 11 |
Total Current Liabilities | 28 | 29 | 19 | 26 | 24 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 13 | 16 | 15 | 15 | 19 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 6 | 8 | 7 | 8 | 9 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 53 | 57 | 42 | 50 | 53 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 47 | 47 | 48 | 49 | 50 |
Capital Surplus | 0 | 0 | 0 | 0 | 0 |
Retained Earnings | -17 | -11 | -6 | -2 | 1 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 29 | 36 | 43 | 47 | 51 |
Total Liabilities & Shareholder's Equity | 82 | 93 | 84 | 96 | 105 |
Total Common Equity | 29 | 36 | 43 | 47 | 51 |
Shares Outstanding | 14.90 | 14.60 | 14.80 | 15.00 | 15.10 |
Book Value Per Share | 1.96 | 2.46 | 2.88 | 3.12 | 3.38 |
Fiscal Year End for Cumberland Pharmaceuticals Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 18 | 19 | 18 | 16 |
Receivables | NA | 10 | 13 | 12 | 15 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 5 | 9 | 11 | 10 |
Other Current Assets | NA | 3 | 2 | 2 | 3 |
Total Current Assets | NA | 36 | 42 | 44 | 44 |
Net Property & Equipment | NA | 0 | 0 | 0 | 0 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 13 | 8 | 7 | 8 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 24 | 28 | 29 | 30 |
Deposits & Other Assets | NA | 3 | 3 | 3 | 3 |
Total Assets | NA | 82 | 88 | 89 | 89 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 14 | 11 | 11 | 11 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 0 | 0 | 0 | 0 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 14 | 16 | 16 | 14 |
Total Current Liabilities | NA | 28 | 27 | 27 | 26 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 13 | 13 | 13 | 16 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 6 | 7 | 7 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 53 | 52 | 53 | 53 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 47 | 47 | 47 | 47 |
Capital Surplus | NA | 0 | 0 | 0 | 0 |
Retained Earnings | NA | -17 | -11 | -10 | -11 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 29 | 36 | 37 | 36 |
Total Liabilities & Shareholder's Equity | NA | 82 | 88 | 89 | 89 |
Total Common Equity | 0 | 29 | 36 | 37 | 36 |
Shares Outstanding | 14.10 | 14.90 | 14.30 | 14.40 | 14.40 |
Book Value Per Share | 0.00 | 1.96 | 2.49 | 2.56 | 2.50 |